Individuals who are heterozygous for CFTR mutations but do not develop cystic fibrosis symptoms, known as carriers, have been found to have an increased risk of developing asthma (Miller et al., 2020; Deletang and Taulan-Cadars, 2022). This evidence concerns the gene CFTR and asthma.